Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies
- Status
- TERMINATED
- Phase
- PHASE2
Clinical Trials Related to Merck Sharp & Dohme LLC
Related studies linked through entity extraction aliases.
Pembrolizumab, Olaparib, and Temozolomide for People With Glioma
- Status
- RECRUITING
- Phase
- PHASE2
Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC)
- Status
- RECRUITING
- Phase
- PHASE2
Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205]
- Status
- TERMINATED
- Phase
- PHASE2
Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in mTNBC Patients
- Status
- UNKNOWN
- Phase
- PHASE2
JAB-BX102 Monotherapy and Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Stick2PrEP Cisgender Women and Trans Individuals
- Status
- RECRUITING
- Phase
- NA
Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours (FORTIFY)
- Status
- COMPLETED
- Phase
- PHASE1
Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA)
- Status
- COMPLETED
- Phase
- PHASE2
Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)
- Status
- COMPLETED
- Phase
- PHASE3
A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma
- Status
- COMPLETED
- Phase
- PHASE2
IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine Carcinosarcoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Impact of Obesity on the Pharmacokinetics of Imipenem-Relebactam in ICU Patients
- Status
- WITHDRAWN
- Phase
- PHASE4
A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)
- Status
- COMPLETED
- Phase
- PHASE2